FrancophonIA/ELRC3.0 huggingface dataset:
English: The European Commission issued an EU-wide legally binding decision to implement these changes on 16 December 2014.
Estonian: Euroopa Komisjon tegi nende muudatuste rakendamiseks kogu Euroopa Liidus õiguslikult siduva otsuse 16. detsembril 2014.
English: Plendil contains the active substance felodipine.
Estonian: Plendil sisaldab toimeainena felodipiini.
English: On 23 October 2014, the European Medicines Agency completed a review of Plendil and associated names.
Estonian: 23. oktoobril 2014 lõpetas Euroopa Ravimiamet Plendili ja sarnaste nimetuste ülevaatamise.
English: The CHMP also harmonised other sections of the SmPC, including sections 4.4 (special warnings and precautions for use), 4.6 (fertility, pregnancy and lactation) and 4.8 (side effects).
Estonian: Inimravimite komitee ühtlustas ka ravimi omaduste kokkuvõtte muud lõigud, sh lõigud 4.4 (erihoiatused ja ettevaatusabinõud kasutamisel), 4.6 (fertiilsus, rasedus ja imetamine) ning 4.8 (kõrvaltoimed).
English: The CHMP agreed to include the following contraindications in the product information: hypersensitivity (allergy) to felodipine or to any other ingredients; pregnancy; decompensated heart failure (worsening of symptoms in patients with heart problems); acute myocardial infarction (heart attack); unstable angina pectoris (a type of chest pain that happens suddenly, even at rest or asleep, and which may lead to a heart attack), and certain types of heart valve and bloodflow obstructions.
Estonian: Inimravimite komitee nõustus, et ravimiteabesse lisatakse järgmised vastunäidustused: ülitundlikkus (allergia) felodipiini või ravimi mis tahes koostisaine suhtes, rasedus, dekompenseeritud südamepuudulikkus (südameprobleemidega patsientide sümptomite halvenemine), äge müokardiinfarkt (südameinfarkt), ebastabiilne stenokardia (valu rinnus, mis tekib ootamatult, isegi puhkamise või magamise ajal, ja mis võib tuua kaasa südameinfarkti) ning teatud tüüpi südameklapi ja südame verevarustuse takistused.
English: After reviewing the available data supporting the medicine's use, the CHMP agreed that Plendil can be used to treat the following:
Estonian: Ravimi kasutamist toetavate andmete läbivaatamise järel nõustus inimravimite komitee, et Plendilit tohib kasutada järgmistel näidustustel:
English: In view of this, on 12 November 2013 the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Plendil in the EU.
Estonian: Seepärast tegi Euroopa Komisjon 12. novembril 2013 inimravimite komiteele esildise Plendili müügilubade ühtlustamiseks Euroopa Liidus.
English: • stable angina pectoris (a type of angina pectoris that occurs with activity or stress).
Estonian: • stabiilne stenokardia (stenokardia, mis tekib pingutuse või stressi korral).
English: Having harmonised the indications, the CHMP also harmonised recommendations on the doses and recommendations for special populations.
Estonian: Pärast näidustuste ühtlustamist ühtlustas inimravimite komitee ka soovitatavad annused ja soovitused eripopulatsioonide kohta.
English: The Committee also agreed that Plendil should no longer be recommended to treat ‘vasospastic angina pectoris' (another type of angina pectoris caused by spasms in the vessels supplying blood to the heart), because the available data to support this use were considered too limited.
Estonian: Samuti leppis inimravimite komitee kokku, et Plendilit ei tohi enam soovitada vasospastilise stenokardia (stenokardia, mida põhjustavad südame veresoonte spasmid) ravis, sest seda näidustust toetavaid olemasolevaid andmeid peeti liiga piiratuiks.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there is a need to harmonise the prescribing information for Plendil and associated names in the European Union (EU).
Estonian: Ravimiameti inimravimite komitee järeldas, et Plendili ja sarnaste nimetuste määramise teave tuleb Euroopa Liidus (EL) ühtlustada.
English: It is also used to treat angina pectoris (chest pain that occurs due to problems with the blood flow to the heart).
Estonian: Seda kasutatakse ka stenokardia (valu rinnus, mida põhjustavad südame verevarustuse probleemid) ravis.
English: Plendil is a medicine used to treat hypertension (high blood pressure).
Estonian: Plendil on hüpertensiooni (kõrge vererõhu) ravim.
English: As Plendil has been authorised in the EU via national procedures, this has led to divergences across Member States in the way the medicine can be used, as seen in differences in the SmPCs (summary of product characteristics), labelling and package leaflets in the countries where the medicine is marketed.
Estonian: Et Plendil on Euroopa Liidus heaks kiidetud riiklike menetluste kaudu, ei ühti ravimit turustatavates liimesriikides ravimi näidustused, mistõttu eri riikides on ravimi omaduste kokkuvõte, märgistus ja pakendi infoleht erinevad.
English: The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets for Plendil should be harmonised across the EU.
Estonian: Esitatud andmete hindamise ja komitees toimunud teadusliku arutelu põhjal järeldas inimravimite komitee, et Plendili ravimi omaduste kokkuvõtted, märgistused ja pakendi infolehed tuleb Euroopa Liidus ühtlustada.
English: The medicine is available as prolonged release tablets (2.5, 5 and 10 mg) which release the active substance over an extended period of time.
Estonian: Ravimit turustatakse toimeainet prolongeeritult ehk pikema aja jooksul vabastavate tablettidena (2,5 mg, 5 mg ja 10 mg).
English: The labelling and package leaflet were also revised in line with the changes to the SmPC.
Estonian: Kooskõlas ravimi omaduste kokkuvõttesse tehtud muudatustega vaadati läbi ka pakendi märgistus ja infoleht.
English: Oral use blister (PVC/PVDCalu/PET/paper)
Estonian: Suukaudne blister (PVC/PVDCalu/PET/paber)
English: 200 mg Film-coated tablet
Estonian: 200 mg Õhukese polümeerikattega tablett
English: Immediate Packaging Pack size
Estonian: Sisepakendi iseloomustus
English: MA (EU) number (Invented) name Strength Pharmaceutical form Route of administration
Estonian: Tugevus Ravimvorm
English: Ref. EMEA/CHMP/494721/2008
Estonian: London, 3. september 2008 Viide: EMEA/CHMP/494728/2008
English: Losartan is indicated for the treatment of hypertension.
Estonian: Losartaani kasutamine on näidustatud hüpertensiooni raviks.
English: Cozaar and associated names, 12,5 mg, 25mg, 50 mg, 100 mg, film-coated tablets is an orally active angiotensin II (Ang- II) receptor antagonist, losartan, acting on the AT1 receptor subtype, thus blocking the effect of Ang-II in the renin angiotensin system (RAS) cascade.
Estonian: Cozaar ja sarnased nimetused (12,5 mg, 25 mg, 50 mg ja 100 mg õhukese polümeerikattega tabletid) on suu kaudu toimiv angiotensiin II (Ang-II) retseptori antagonistid, mis sisaldavad toimeainena losartaani, mis toimib retseptori AT1 alatüübile, blokeerides seega reniini-angiotensiini süsteemi (RAS) kaskaadis Ang-II toime.
English: Losartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes, and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).
Estonian: Losartaan võib aeglustada ka diabeetilise nefropaatia süvenemist ja on näidustatud ka neeruhaiguse süvenemise aeglustamiseks 2. tüüpi diabeediga ja mikroalbuminuuria (>30 mg/24 h) või proteinuuriaga (>900 mg/24 h) patsientidel.
English: On 23 February 2007, Denmark presented to the EMEA a referral under Article 30 of Directive 2001/83/EC, as amended, in order to harmonise the nationally authorised summaries of product characteristics, package leaflet and labelling of the medicinal product Cozaar and associated names for the following indications: Treatment of essential hypertension; Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus with proteinuria > 0.5 g/day as part of an antihypertensive treatment; Reduction of risk of stroke in hypertensive patients with left ventricular hypertrophy documented by ECG; Treatment of chronic heart failure (in patients ≥ 60 years), when treatment with ACE inhibitors is not considered suitable due to incompatibility, especially cough, or contraindication.
Estonian: 23. veebruaril 2007 esitas Taani Euroopa Ravimiametile muudetud direktiivi 2001/83/EÜ artikli 30 alusel esildise, et ühtlustada ravimi Cozaar ja sarnaste nimetuste ravimi omaduste kokkuvõtted, pakendi infolehed ja märgistus järgmiste näidustuste jaoks: essentsiaalse hüpertensiooni ravi; neeruhaiguse ravi hüpertensiooni ning 2. tüüpi diabeedi ja >0,5 g/ööpäevas proteinuuriaga patsientidel osana antihüpertensiivsest ravist; insuldiriski vähendamine hüpertensiooniga patsientidel, kellel esineb elektrokardiogrammiga dokumenteeritud vasaku vatsakese hüpertroofia; kroonilise südamepuudulikkuse ravi (≥60-aastastel patsientidel), kui ravi angiotensiinkonvertaasi inhibiitoritega ei peeta sobivaks sobimatuse, eriti köha, või vastunäidustuste tõttu.
English: The CHMP gave a positive opinion on 24 April 2008 recommending the harmonisation of the SPC, labelling and package leaflet for Cozaar and associated names.
Estonian: Inimravimikomitee esitas positiivse arvamuse 24. aprillil 2008, soovitades ühtlustada Cozaari ja sarnaste nimetuste ravimi omaduste kokkuvõtted, märgistused ja pakendi infolehed.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 30 REFERRAL FOR Cozaar and associated names International Non-Proprietary Name (INN): losartan
Estonian: INIMRAVIMIKOMITEE ARVAMUS PÄRAST ARTIKLI 30 KOHAST ESILDIST, MIS KÄSITLES RAVIMIT Cozaar ja sarnased nimetused
English: It is taken by mouth once daily.
Estonian: Incresynci võetakse suu kaudu üks kord päevas.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Incresync on 19 September 2013.
Estonian: Euroopa Komisjon andis Incresynci müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 19. septembril 2013.
English: Incresync alogliptin / pioglitazone
Estonian: Incresync alogliptiin/pioglitasoon
English: The full EPAR for Incresync can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Incresynci kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Incresync
Estonian: Muu teave Incresynci kohta
English: A risk management plan has been developed to ensure that Incresync is used as safely as possible.
Estonian: Töötati välja riskijuhtimisstrateegia, et tagada Incresynci võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Incresync?
Estonian: Mis meetmed võetakse, et tagada Incresynci ohutu ja efektiivne kasutamine?
English: HbA1c levels were measured after 26 weeks in the first study and 52 weeks in the second study.
Estonian: HbA1c sisaldust mõõdeti esimeses uuringus 26 nädala möödudes ja teises uuringus 52 nädala möödudes.
English: What is Incresync and what is it used for?
Estonian: Mis on Incresync ja milleks seda kasutatakse
English: Incresync has been studied in two main studies involving 1,296 patients with type-2 diabetes that was not well controlled by previous treatment.
Estonian: Incresynci uuriti kahes põhiuuringus, milles osales 1296 II tüüpi diabeediga patsienti, kelle haigus ei allunud piisavalt varasemale ravile.
English: The choice of tablet strength to start with depends on the patient's current treatment.
Estonian: Tableti tugevuse valik ravi alguses sõltub ravimist, mida patsient juba võtab.
English: Incresync is available as tablets (12.5 or 25 mg alogliptin and 30 mg pioglitazone; 12.5 or 25 mg alogliptin and 45 mg pioglitazone) and can only be obtained with a prescription.
Estonian: Incresynci turustatakse tablettidena (12,5 või 25 mg alogliptiini ja 30 mg pioglitasooni; 12,5 või 25 mg alogliptiini ja 45 mg pioglitasooni) ja see on retseptiravim.
English: In addition, the company that markets Incresync will produce educational materials for doctors prescribing the medicine, which will cover the possible risk of heart failure and bladder cancer with treatments that contain pioglitazone, the criteria for selecting patients and the need to review treatment regularly and stop treatment if patients are no longer benefiting.
Estonian: Lisaks varustab Incresynci turustav ettevõte ravimit väljakirjutavad arstid teabematerjaliga, milles selgitatakse südamepuudulikkuse ja põievähi võimalikku riski pioglitasooni sisaldavate ravimitega, patsientide valikukriteeriume ja vajadust ravi regulaarselt üle vaadata ning see lõpetada, kui patsiendid sellest enam kasu ei saa.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that Incresync's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee järeldas, et Incresynci kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: When added to pioglitazone, the improvement was a fall of 0.47% at a dose of alogliptin of 12.5 mg, and 0.61% for alogliptin 25 mg. Incresync was at least as effective as pioglitazone and metformin in reducing HbA1c.
Estonian: Pioglitasoonile lisamisel esines 0,47% vähenemine alogliptiini annusega 12,5 mg ja 0,61% vähenemine alogliptiini annusega 25 mg. Incresync oli HbA1c vähendamisel vähemalt sama efektiivne kui pioglitasoon ja metformiin.
English: Why is Incresync approved?
Estonian: Miks Incresync heaks kiideti?
English: It must also not be used in patients who have or have ever had heart failure or bladder cancer, those with reduced liver function, diabetic ketoacidosis (a serious condition that can occur in diabetes), or blood in the urine that has not been properly investigated.
Estonian: Samuti ei tohi seda kasutada patsiendid, kellel on või on kunagi olnud südamepuudulikkus või põievähk, halvenenud maksatalitlus, diabeetiline ketoatsidoos (raske seisund, mis võib esineda diabeedi puhul) või veri uriinis, mida ei ole korralikult uuritud.
English: Both studies showed that the combination of active substances in Incresync could produce a small but clinically relevant improvement in HbA1c.
Estonian: Mõlemad uuringud näitasid, et Incresynci toimeainete kombinatsioon põhjustab väikest, kuid kliiniliselt olulist HbA1c sisalduse paranemist.
English: Incresync must not be used in patients who are hypersensitive (allergic) to the active substances or any of the ingredients or who have had serious allergic reactions to any dipeptidyl-peptidase-4 (DPP 4) inhibitor.
Estonian: Incresynci ei tohi kasutada patsiendid, kes on toimeainete või ravimi muude koostisainete suhtes ülitundlikud (allergilised) või kellel on olnud raskeid allergilisi reaktsioone mõne dipeptidüülpeptidaas-4 (DPP-4) inhibiitori suhtes.
English: The most common side effects with Incresync (which may affect up to 1 in 10 people) are upper respiratory tract infections (colds), sinusitis, headache, nausea (feeling sick), dyspepsia (heartburn), abdominal pain (tummy ache), pruritus (itching), myalgia (muscle pain), peripheral oedema (swelling in arms and legs) and weight gain.
Estonian: Incresynci kõige sagedamad kõrvalnähud (võivad esineda kuni 1 patsiendil 10st) on ülemiste hingamisteede infektsioonid (külmetus), sinusiit, peavalu, iiveldus, düspepsia (kõrvetised), kõhuvalu, sügelus, müalgia (lihasvalu), perifeerne turse (käte ja jalgade paistetus) ja kehakaalu tõus.
English: Pioglitazone makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Estonian: Pioglitasoon suurendab rakkude (rasva-, lihas- ja maksarakud) tundlikkust insuliini suhtes, mis tähendab, et organism kasutab paremini enda toodetavat insuliini.
English: Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Estonian: II tüüpi diabeet on haigus, mille korral kõhunäärmes ei teki vere glükoosisisalduse reguleerimiseks piisavalt insuliini või organism ei suuda insuliini efektiivselt kasutada.
English: Incresync can also be used as a replacement tablet (supplying both alogliptin and pioglitazone) in patients who are already being treated with alogliptin and pioglitazone given separately.
Estonian: Incresynci võib samuti kasutada asendustabletina (mis sisaldab nii alogliptiini kui ka pioglitasooni) patsientidel, keda juba ravitakse eraldi manustatavate alogliptiini ja pioglitasooniga.
English: It is not intended to provide practical advice on how to use Incresync.
Estonian: Hindamisaruandes ei anta Incresynci kasutamise praktilisi nõuandeid.
English: The active substances in Incresync, alogliptin and pioglitazone, work in different ways to help correct this.
Estonian: Incresynci toimeained alogliptiin ja pioglitasoon toimivad erineval moel, aidates seda puudujääki korrigeerida.
English: If patients are also taking metformin, lower doses of metformin or pioglitazone may need to be given to reduce the risk of hypoglycaemia (low blood sugar levels).
Estonian: Kui patsient võtab ka metformiini, võib vajalikuks osutuda metformiini või pioglitasooni annuste vähendamine, et vähendada hüpoglükeemia (vere glükoosivaeguse) riski.
English: What are the risks associated with Incresync?
Estonian: Mis riskid Incresynciga kaasnevad?
English: HbA1c levels give an indication of how well the blood glucose is controlled.
Estonian: HbA1c sisaldus näitab vere glükoosisisalduse reguleeritust.
English: Regarding safety, Incresync's safety profile was consistent with that seen with the individual components.
Estonian: Ohutuse osas vastas Incresynci ohutusprofiil selle koostisosade omale.
English: • in patients who are not satisfactorily controlled with pioglitazone alone, and who cannot be treated with metformin (another diabetes medicine);
Estonian: • patsientidel, kelle vere glükoosisisaldus ei ole piisavalt reguleeritud üksnes pioglitasooniga ja keda ei saa ravida metformiiniga (teine diabeediravim);
English: • together with metformin, in patients who are not satisfactorily controlled with a combination of pioglitazone and metformin.
Estonian: • koos metformiiniga patsientidel, kelle vere glükoosisisaldus ei ole piisavalt reguleeritud pioglitasooni ja metformiini kombinatsiooniga.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Incresync, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Incresynci ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The CHMP therefore considered that the combination of alogliptin and pioglitazone in Incresync is of benefit to patients.
Estonian: Seetõttu järeldas inimravimite komitee, et Incresyncis sisalduv alogliptiini ja pioglitasooni kombinatsioon on patsientidele kasulik.
English: This is a summary of the European public assessment report (EPAR) for Incresync.
Estonian: See on ravimi Incresync Euroopa avaliku hindamisaruande kokkuvõte.
English: Alogliptin is licensed in the EU as Vipidia.
Estonian: Alogliptiinil on ELis müügiluba ravimina Vipidia.
English: For practical information about using Incresync, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Incresynci kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Incresync is a diabetes medicine containing the active substances alogliptin and pioglitazone.
Estonian: Incresync on diabeedi (suhkurtõve) ravim, mis sisaldab toimeainetena alogliptiini ja pioglitasooni.
English: If patients were previously taking pioglitazone and alogliptin separately, Incresync should be used in a strength that continues to provide the same doses.
Estonian: Kui patsient sai varem pioglitasooni ja alogliptiini eraldi, tuleb Incresynci kasutada tugevuses, mis annab samad annused.
English: Pioglitazone is authorised in the EU as Actos and associated names.
Estonian: Pioglitasoonil on ELis müügiluba ravimina Actos ja sarnased nimetused.
English: The dose should be lowered in patients with moderately reduced kidney function.
Estonian: Mõõdukalt vähenenud neerutalitlusega patsientidel tuleb annust vähendada.
English: How is Incresync used?
Estonian: Kuidas Incresynci kasutatakse?
English: For the full list of all side effects reported with Incresync, see the package leaflet.
Estonian: Incresynci kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: For more information about treatment with Incresync, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Incresynciga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It is used as an addition to diet and exercise in adults with type 2 diabetes to improve the control of blood glucose (sugar) levels:
Estonian: Seda kasutatakse koos dieedi ja füüsilise koormusega II tüüpi diabeediga täiskasvanutel, et parandada vere glükoosisisalduse reguleeritavust organismis:
English: Alogliptin is a dipeptidyl-peptidase-4 (DPP 4) inhibitor.
Estonian: Alogliptiin on dipeptidüülpeptidaas-4 (DPP-4) inhibiitor, mis blokeerib organismis inkretiinhormoonide lagunemise.
English: In both studies, the main measure of effectiveness was the change in the level of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached.
Estonian: Mõlemas uuringus oli efektiivsuse põhinäitaja glükosüülitud hemoglobiini (HbA1c; hemoglobiin, millele on kinnitunud glükoos) sisalduse muutus.
English: The CHMP considered that adding alogliptin to existing treatment with pioglitazone with or without metformin had shown to produce modest but clinically relevant improvements in HbA1c.
Estonian: Inimravimite komitee leidis, et alogliptiini lisamine olemasolevale ravile pioglitasooniga (koos metformiiniga või ilma) põhjustab mõõdukat, kuid kliiniliselt olulist HbA1c sisalduse paranemist.
English: How does Incresync work?
Estonian: Kuidas Incresync toimib?
English: If patients were previously taking pioglitazone alone, the strength of Incresync that provides the same dose of pioglitazone should be used.
Estonian: Kui patsient sai varem ainult pioglitasooni, tuleb Incresynci kasutada tugevuses, mis annab sama annuse pioglitasooni.
English: What benefits of Incresync have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Incresynci kasulikkus?
English: As a result of the action of both active substances, blood glucose levels are reduced and this helps to control type-2 diabetes.
Estonian: Mõlema toimeaine toimel vere glükoosisisaldus väheneb, mis aitab ravida II tüüpi diabeeti.
English: In the other study the effects of adding alogliptin to existing treatment with pioglitazone and metformin was compared with increasing the doses of pioglitazone.
Estonian: Alogliptiini lisamist olemasolevale ravile pioglitasooni ja metformiiniga võrreldi teises uuringus pioglitasooni annuste suurendamisega.
English: One of the studies compared the effects of alogliptin with placebo (a dummy treatment) when used as an add-on to existing treatment with pioglitazone (the same combination as in Incresync), with or without metformin or another diabetes medicine.
Estonian: Alogliptiini lisati olemasolevale ravile pioglitasooniga (sama kombinatsioon kui Incresyncis) koos metformiini või muu diabeediravimiga või ilma selleta.
English: By blocking the breakdown of Incretin hormones in the blood, alogliptin prolongs their action in stimulating the pancreas to produce more insulin when blood glucose levels are high.
Estonian: Kui vere glükoosisisaldus on suur, stimuleerib alogliptiin kõhunääret tekitama rohkem insuliini, suurendades inkretiinhormoonide sisaldust veres.